Seer defends its pioneering Proteograph® Product Suite intellectual property (IP)

REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a patent infringement suit against Nanomics Biotechnology Co., Ltd. The asserted patents, U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, protect Seer's intellectual property in the field of nanoparticle protein enrichment. Brigham and Women's Hospital is joining this lawsuit as well.

Seer has imagined and pioneered the first solution for standardized, robust, deep unbiased proteomics and has a large patent portfolio of more than 250 patent applications and issued patents, including 84 issued patents worldwide. A large portion of Seer's patents defend IP integral to Seer's Proteograph® Product Suite. As recent evidence regarding the strength of our IP, on March 23, the Patent Trial and Appeal Board's issued a Final Written Decision in an Inter Partes Review (IPR) of U.S. Patent No. 11,435,360 upholding key commercially important claims in Seer's nano- and micro-particle protein enrichment patent. This successful IPR outcome serves as an example of the strengths of our carefully constructed IP estate.